Seeking Alpha

More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for...

More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for lab tests could disproportionately hurt BRLI due to its exposure to blood-based cancer tests — rates for lymphoma tests could rise 70% or more, analysts say. Also moving on the news is Quest Diagnostics (DGX +1.4%) which William Blair thinks will be the least affected, while shares of Neogenomics (NEO -15.4%) plummet on above average volume.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector